Literature DB >> 12534854

Testosterone supplementation therapy for older men: potential benefits and risks.

David A Gruenewald1, Alvin M Matsumoto.   

Abstract

Serum testosterone levels decline gradually and progressively with aging in men. Many manifestations associated with aging in men, including muscle atrophy and weakness, osteoporosis, reduced sexual functioning, and increased fat mass, are similar to changes associated with testosterone deficiency in young men. These similarities suggest that testosterone supplementation may prevent or reverse the effects of aging. A MEDLINE search was performed to identify studies of testosterone supplementation therapy in older men. A structured, qualitative review was performed of placebo-controlled trials that included men aged 60 and older and evaluated one or more physical, cognitive, affective, functional, or quality-of-life outcomes. Studies focusing on patients with severe systemic diseases and hormone deficiencies related to specific diseases were excluded. In healthy older men with low-normal to mildly decreased testosterone levels, testosterone supplementation increased lean body mass and decreased fat mass. Upper and lower body strength, functional performance, sexual functioning, and mood were improved or unchanged with testosterone replacement. Variable effects on cognitive function were reported, with improvements in some cognitive domains (e.g., spatial, working, and verbal memory). Testosterone supplementation improved exercise-induced coronary ischemia in men with coronary heart disease, whereas angina pectoris was improved or unchanged. In a few studies, men with low testosterone levels were more likely to experience improvements in lumbar bone mineral density, self-perceived functional status, libido, erectile function, and exercise-induced coronary ischemia with testosterone replacement than men with less marked testosterone deficiency. No major unfavorable effects on lipids were reported, but hematocrit and prostate specific antigen levels often increased. Based on these results, testosterone supplementation cannot be recommended at this time for older men with normal or low-normal testosterone levels and no clinical manifestations of hypogonadism. However, testosterone replacement may be warranted in older men with markedly decreased testosterone levels, regardless of symptoms, and in men with mildly decreased testosterone levels and symptoms or signs suggesting hypogonadism. The long-term safety and efficacy of testosterone supplementation remain uncertain. Establishment of evidence-based indications will depend on further demonstrations of favorable clinical outcomes and symptomatic, functional, and quality-of-life benefits in carefully performed, long-term, randomized, placebo-controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534854     DOI: 10.1034/j.1601-5215.2002.51018.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  56 in total

1.  GPRC6A mediates the non-genomic effects of steroids.

Authors:  Min Pi; Abby L Parrill; L Darryl Quarles
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

2.  Testosterone restores respiratory long term facilitation in old male rats by an aromatase-dependent mechanism.

Authors:  N R Nelson; I M Bird; M Behan
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

Review 3.  [Therapy of the "aging male"].

Authors:  T Diemer; E W Hauck; V Rohde; W Weidner
Journal:  Urologe A       Date:  2005-10       Impact factor: 0.639

Review 4.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

5.  Gerstmann syndrome complicating polycythemia secondary to anabolic steroid use.

Authors:  Nina Long; Satnaam Bassi; Don Pepito; Hossein Akhondi
Journal:  BMJ Case Rep       Date:  2019-06-06

6.  Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial.

Authors:  Vivian N Hawkins; Karen Foster-Schubert; Jessica Chubak; Bess Sorensen; Cornelia M Ulrich; Frank Z Stancyzk; Stephen Plymate; Janet Stanford; Emily White; John D Potter; Anne McTiernan
Journal:  Med Sci Sports Exerc       Date:  2008-02       Impact factor: 5.411

Review 7.  Optimal management of sarcopenia.

Authors:  Louise A Burton; Deepa Sumukadas
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

Review 8.  The osteoporotic male: overlooked and undermanaged?

Authors:  Bruno Madeo; Lucia Zirilli; Giovanni Caffagni; Chiara Diazzi; Alessia Sanguanini; Elisa Pignatti; Cesare Carani; Vincenzo Rochira
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 9.  The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.

Authors:  Panagiota Manolakou; Roxani Angelopoulou; Chris Bakoyiannis; Elias Bastounis
Journal:  Reprod Biol Endocrinol       Date:  2009-05-12       Impact factor: 5.211

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.